As 2021 draws near, we move closer to an important milestone that changed and aided the type 1 diabetes (T1D) community in an enormous way – the 100th year of insulin.
We are asking the government to renew crucial funds for T1D research
More choices for our T1D community: New Pumps Approved in BC
There’s good news for pumpers in BC! BC Pharmacare has added YpsoPump by YpsoMed to its Tier 1 list of approved insulin pumps. BC residents with type 1 diabetes of all ages can now choose between the Omnipod by Insulet or the YpsoPump under the province’s pump program.
Access For All Goes West
JDRF’s attention has been focused on Canada’s west coast increasingly as the BC government inches closer to a decision on whether or not to cover continuous glucose monitoring (CGM) and flash glucose monitoring (FGM) systems. BC Pharmacare commissioned a health technology assessment on these technologies more than a year ago but the results have yet to be released.
London, UK sees localized increase in pediatric T1D diagnoses – but experts say too early to blame COVID-19
A recent increase in type 1 diabetes (T1D) diagnoses in children under 18 in some hospitals in north-west London, UK, has triggered news stories that COVID-19 could cause the disease in children. But experts have stressed that the locally reported increase in diagnoses is not yet clearly linked to the pandemic.
Type 1 diabetes and COVID-19: Going back to school
As students across Canada get ready to head back to school—some after nearly 6 months of being away—parents have many questions. The first is usually, “Is it safe to send my child back to school during this pandemic?”
Here are some things to consider when making a decision about sending your child with type 1 diabetes (T1D) back to school.
Landmark trial of T1D-related kidney disease misses primary outcome, but provides valuable lessons
Kidney disease remains one of the leading complications of diabetes, including the need for dialysis or kidney transplant. This led to the Preventing Early Renal Loss in Diabetes (PERL) trial, a joint initiative between investigators across North America and Denmark.
Making the best of the COVID-19 situation
With visits to healthcare professionals (HCPs) now mostly virtual, tele-health and Zoom meetings now the norm, there comes a heavier reliance on self-monitoring.
To our community and our partners: Thank you
We are incredibly grateful to our partners, and the entire T1D community for their commitment and support as we work together to move type 1 diabetes research forward faster than ever.
Here’s why these families are In to End Diabetes
This month, we wanted to recognize some of our amazing monthly donors and thank them for their support. Their stories will help you understand why they’re In to End Diabetes.
Advocacy in a post-Covid-19 world
Your stories make all the difference.
Updates from the Teplizumab Trial: You’re Not Going to Believe the Results
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for over two years—the onset of type 1 diabetes (T1D) in participants with a high risk of developing the disease. This was the first ever study in humans to show a delay in the onset of T1D. But it doesn’t stop there. JDRF has very promising updated results.
Virtual care for T1D during the COVID-19 pandemic – and beyond
The type 1 diabetes (T1D) community has always embraced new technology – with insulin pumps, continuous glucose monitors (CGMs), flash glucose monitors (FGMs), and a variety of T1D-focused apps rapidly becoming essential tools for many people. It’s no surprise, then, that the T1D community has quickly adapted to accessing healthcare virtually.
